IP counsel to multiple east coast venture funds for numerous investment transactions in the small molecule therapeutics, gene therapy, and diagnostic spaces, and IP counsel to certain portfolio companies of those funds.

IP counsel to multiple west coast venture funds for numerous investment transactions in the gene therapy, immunotherapy, and small molecule therapeutics spaces, and IP counsel to certain of the portfolio companies of those funds.

IP counsel to multiple European venture funds for numerous investment transactions in the medical device space, and IP counsel to certain of the portfolio companies of those funds.

IP counsel to clinical-stage biotechnology company Latigo Biotherapeutics with a $135 million Series A financing to develop nonopioid pain medication.

IP counsel to biotechnology company Aliada Therapeutics in a co-development agreement with Chiesi Global Rare Diseases to develop a novel blood-brain barrier-crossing platform technology in lysosomal storage disorders.

IP counsel to biotech startup Kate Therapeutics (KateTx) in its exclusive licensing deal with Astellas Pharma Inc. to develop and commercialize a gene therapy for a debilitating muscle disorder.

Representation of Acelyrin, an immunology-focused drug developer, as IP counsel in connection with its $540 million initial public offering, one of the highest amounts for a U.S. IPO by a traditional biopharma company.

IP counsel to Capsida deal team for collaboration deal with Prevail, a Wholly Owned Subsidiary of Eli Lilly.

IP counsel to Tmunity deal team for acquisition by Kite/Gilead.

IP counsel to Capsida deal team for collaboration deal with Abbvie.

IP counsel for Aerovate IPO.

IP counsel to venture backed immunotherapeutics company and led IP aspects of deal team in significant collaboration with a leading pharmaceutical company.

Developing patent portfolio for an emerging company with a small molecule cancer asset in clinical trials.

Developing patent portfolio for an emerging company with a small molecule assert for heart disease in clinical trials and have led company through multiple rounds of diligence with investors.

Representing a U.S. university in continued development of multiple mass spectrometry patent portfolios that presently includes over 200 patents worldwide covering various different mass spectrometry technologies that have been licensed to numerous leading analytical instrument companies as well as other emerging companies.

Represented west coast venture fund in licensing and IP due diligence for joint venture deal with a German small molecule therapeutics company to form a new entity to develop a suite of neurology small molecule assets, with continued IP representation of the new entity.

Developing patent portfolio for medical device product for medical device company for treatment of acute decompensated heart failure and have led the company through multiple investor diligences.

Developing patent portfolio for a personalized cellular immunotherapy for a clinical-stage biotechnology company in which the product is presently in clinical trials and have led the company though multiple investor diligences.

Negotiated a collaboration agreement between a preclinical digital pathology company and a premier contract research organization for clinical and non-clinical services.

Developed patent portfolio for tools company in the immunotherapeutics space that drove investment and commercial supply agreement with a leading material science and life science products company and subsequent sale of the company to a clinical stage immunotherapy company, with continued IP representation after the sale.

Developed patent portfolio for diagnostic company with cell technology and machine learning models that characterize the immune system that drove sale of company to diagnostic company in the immunotherapy space.

Developing patent portfolio for Irish medtech company with device for treating nasal disorders that has driven multiple successful rounds of investment.

Developing patent portfolio for emerging British company developing safe and effective drug delivery systems for cell and gene therapeutics and have led the company through multiple investor diligences.

Developing patent portfolio for company with next generation cell therapy technology for treatment of solid tumors and have led the company through multiple investor diligences.

Developing patent portfolio for emerging company for a suite of specialized tools for minimally invasive orthopedic procedures and have led the company through multiple investor diligences.

Developing patent portfolios for numerous additional emerging companies, such as:

• Therapeutics company with a small molecule asset for certain neuropsychiatric and neurological disorders.
• Immunotherapy company with an asset for cancer treatment.
• Gene therapy company developing assets for treating neurological disorders.
• Therapeutics company with a small molecule asset for certain cancers.
• Israeli medical device company with device for treatment of heart failure.
• Therapeutics company with a small molecule asset for treating neurological disorders.
• Therapeutics company with a biologics asset for treating renal disorders.
• Therapeutics company with a small molecule asset for treating pain disorders.
• Digital health company with diagnostic device and proprietary software platform for assessing male fertility.
• Digital health company with proprietary software platform for virtual surgical simulations.
• Synthetic biology company with proprietary technology for developing cotton in vitro.
• Synthetic biology company with proprietary technology for developing various different chemical compounds at scale.
• Digital health company with diagnostic methods and proprietary software platform for care management solution for workers’ injury prevention and recovery.
• Therapeutics company with products for delivery of drugs to the gastrointestinal system.
• Therapeutics company with small molecule asset for treating kidney disorders.
• Digital health company with software platform for modeling delivery of compounds to different tissues.
• Digital health company with software platform for assessing wellness and diagnosing psychiatric disorders.
• Therapeutics company with products for treating inflammatory conditions.
• Gene therapy company developing proprietary vectors for delivering a gene therapy.
• Medical device company developing a product for treating infections.
• Medical device company with proprietary software platform developing a product for assessing and monitoring water quality.
• Medical device company with image guided solutions for minimally invasive procedures.
• Microfluidics company developing microfluidic based immunoassays.
• Medical device company developing bone grafting products.
• Diagnostics company with methods for assessing neurological conditions.
• Medical device company developing an ultrasound-based platform for drug delivery.

Developed patent portfolio for T cell therapy company that was acquired by a neuro-immunology company, with continued IP representation of the company after acquisition.

Core member of team that developed and obtained a patent portfolio of over 150 patents for a microfluidics and genetic diagnostics company that was acquired by a biopharmaceutical company for over $75 million, with continued IP representation of the company after acquisition.

Developed patent portfolio for an ablation catheter company to treat atrial fibrillation that was acquired by an Italian medical device company, with continued IP representation of the company after acquisition.

Core member of multidisciplinary team for cross-border transaction for sale of numerous small molecule assets to a leading pharmaceutical company. The work involved analyzing over 50 patents covering the numerous small molecule assets along with analysis of numerous licenses and litigation settlement agreements. The work also involved negotiating IP aspects of the transaction documents.

Core member of team that developed and obtained a patent portfolio of over 100 patents for a next generation sequencing company that were sold to a leading sequencing company.

Core member of team that developed and obtained a patent portfolio of over 30 patents for a fluidics and molecular diagnostic company that was sold to large molecular diagnostic company.

Core member of team that developed patent portfolio for a laparoscopic surgical instrument for a medical device company that was sold to a global leader in medical technology.

Core member of team that developed and obtained a patent portfolio of over 30 patents for a microfluidics company that was acquired by a biopharmaceutical company.

Developed patent portfolio for U.S. university in the microfluidics space that was licensed to a diagnostics company.

IP counsel to large imaging guided therapy company and developed multiple patent portfolios in the ultrasound and OCT space.

IP counsel to large healthcare company and developed multiple patent portfolios in the medical records space and the imaging device space.

Represented U.S. university in the genetic diagnostics space and developed patent portfolio that was licensed to an emerging diagnostics and therapeutics company.

Core member of team that developed patent portfolio for medical device company with product in glaucoma space.

Developed patent portfolio for digital health company with diagnostic device and proprietary software platform for analyzing blood and diagnosing a disorder.

Core member of team that developed patent portfolio for digital health company with diagnostic methods and proprietary software platform for assessing infertility.

Developed patent portfolio for medtech company with a device for treating neurological disorders.